Myelodysplastic Syndrome (MDS) is a heterogeneous group of hematologic neoplasms classically described as a clonal disorder of hematopoietic stem cells leading to dysplasia and ineffective hematopoiesis in the bone marrow.
&nbsp;
Some of the major symptoms of Myelodysplastic Syndrome include fatigue, shortness of breath, unusual paleness, easy or unusual bruising or bleeding, pinpoint-sized red spots just beneath the skin, and frequent infections. Genetic Syndromes, familial MDS, gender, and age, are some of the major risk factors for Myelodysplastic Syndrome.
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/myelodysplastic-syndrome-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Myelodysplastic Syndrome Epidemiology Insights</a> Observed in 2020
<ul>
<li class="ql-align-justify">The incident population of Myelodysplastic Syndrome in 7MM was found to be 41,586</li>
<li class="ql-align-justify">The incident cases of Myelodysplastic Syndrome in the US were observed to be 20,428</li>
<li class="ql-align-justify">The incident cases of Myelodysplastic Syndrome in Germany were estimated to be 4,515. While France, the UK, and Spain had 4,371, 3,302, and 2,010 cases respectively.&nbsp;</li>
<li class="ql-align-justify">Japan had 3,909 cases of Myelodysplastic Syndrome</li>
</ul>
&nbsp;
Myelodysplastic Syndrome Epidemiology Segmentation in the 7MM for the Study Period 2018-30
<ul>
<li class="ql-align-justify">Total incident population of Myelodysplastic Syndrome</li>
<li class="ql-align-justify">Age-specific incident population of Myelodysplastic Syndrome</li>
<li class="ql-align-justify">Subtype-specific incident population of Myelodysplastic Syndrome</li>
<li class="ql-align-justify">Risk-specific incident population of Myelodysplastic Syndrome</li>
<li class="ql-align-justify">Mutation-specific incident population of Myelodysplastic Syndrome</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market" target="_blank" rel="noopener noreferrer">Myelodysplastic Syndrome Market Insight</a>
The Myelodysplastic Syndrome market size in the 7MM was found to be USD 1,924 million in 2020.
&nbsp;
Myelodysplastic Syndrome Market Drivers
<ul>
<li class="ql-align-justify">Robust pipeline activity</li>
<li class="ql-align-justify">Potential of upcoming therapies</li>
<li class="ql-align-justify">Development of therapies for the second-line setting</li>
<li class="ql-align-justify">Increasing awareness programs</li>
</ul>
&nbsp;
Myelodysplastic Syndrome Market Barriers
<ul>
<li class="ql-align-justify">Lack of treatment pattern studies in the 7MM</li>
<li class="ql-align-justify">Underdiagnosis of MDS</li>
<li class="ql-align-justify">The high-cost burden of MDS treatment</li>
<li class="ql-align-justify">Progression of patients toward AML</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight" target="_blank" rel="noopener noreferrer">Myelodysplastic Syndrome Emerging Therapies</a>
The emerging drugs in the Myelodysplastic Syndrome market are
<ul>
<li class="ql-align-justify">Roxadustat</li>
<li class="ql-align-justify">Venclexta (Venetoclax) + Azacitidine</li>
<li class="ql-align-justify">Magrolimab &plusmn; Azacitidine</li>
<li class="ql-align-justify">Sabatolimab + Azacitidine</li>
<li class="ql-align-justify">SY-1425 + Azacitidine</li>
<li class="ql-align-justify">Pevonedistat &plusmn; Azacitidine</li>
<li class="ql-align-justify">Glasdegib + Azacitidine/Cytarabine</li>
<li class="ql-align-justify">Imetelstat</li>
<li class="ql-align-justify">Eltanexor (ATG 016; KPT-8602)</li>
<li class="ql-align-justify">Bemcentinib</li>
<li class="ql-align-justify">Enasidenib</li>
<li class="ql-align-justify">CPX-351</li>
<li class="ql-align-justify">Eprenetapopt (APR-246)</li>
<li class="ql-align-justify">Fludarabine + Busulfan &plusmn; Clofarabine</li>
<li class="ql-align-justify">Treosulfan &plusmn; fludarabine</li>
</ul>
And many more.
&nbsp;
Myelodysplastic Syndrome Market Prominent Players
The key companies in the Myelodysplastic Syndrome market are
<ul>
<li class="ql-align-justify">Fibrogen</li>
<li class="ql-align-justify">AbbVie</li>
<li class="ql-align-justify">Gilead Sciences</li>
<li class="ql-align-justify">Novartis</li>
<li class="ql-align-justify">Syros Pharmaceuticals</li>
<li class="ql-align-justify">Takeda</li>
<li class="ql-align-justify">Pfizer</li>
<li class="ql-align-justify">Geron Corporation</li>
<li class="ql-align-justify">Karyopharm Therapeutics/Antengene Corporation</li>
<li class="ql-align-justify">BerGenBio ASA</li>
<li class="ql-align-justify">Bristol Myers Squibb</li>
<li class="ql-align-justify">Jazz Pharmaceuticals</li>
<li class="ql-align-justify">Aprea Therapeutics</li>
<li class="ql-align-justify">Sanofi</li>
<li class="ql-align-justify">Medac</li>
</ul>
And many others

Myelodysplastic Syndrome Market Infographics

Myelodysplastic Syndrome Market

Myelodysplastic Syndrome Market Infographic provides insights into the Market Size, Trends, Treatment, Epidemiology, Companies, and Emerging Therapies